ClinicalTrials.gg
TerminatedNCT01378377Updated Jul 30, 2018Results posted

Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus

A Phase 1 interventional study of Pimasertib and Pimasertib in Advanced Solid Tumor, sponsored by EMD Serono. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-30.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Treatment

Why this study was terminated
The trial was stopped due to the toxicities observed with the combination of pimasertib and temsirolimus.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The research trial is testing the experimental drug pimasertib and the drug Torisel, given together, in the treatment of advanced solid tumors. The primary purpose of the study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of the drug combination.

02

Conditions studied

  • Advanced Solid Tumor

Browse trials for

Keywords

  • MEK inhibitor
  • Temsirolimus
  • Neoplasms
  • Phase I
  • Pimasertib
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 33 is below the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.

First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with or cytologically confirmed solid tumors, either to standard therapy or for which no effective standard therapy is available.
  • Measurable or evaluable disease at baseline by 1.0.
  • Age >= 18 years.
  • Subject has read and understands the form and is willing and able to give informed consent.
  • Performance Status score of less than or equal to (\<=) 1 according to the (ECOG) scale.
  • Women of must have a negative blood pregnancy test at the screening visit.
  • Female subjects of childbearing potential and male subjects with female partners of childbearing potential must be willing to avoid pregnancy by using an adequate method of for 2 weeks prior to screening, during the trial and for 3 months after the last dose of trial medication.

Additional inclusion criteria also apply.

Exclusion criteria

Exclusion Criteria:

  • The subject has previously been treated with mammalian target of rapamycin (mTOR) inhibitor or a mitogen-activated protein kinase (MEK) inhibitor and taken off treatment due to drug-related AEs.
  • The subject has received any of the following:
  • Chemotherapy, immunotherapy, hormonal therapy, biologic therapy, any agent or any other anti-cancer therapy within 28 days (6 weeks for nitrosoureas or mitomycin C) of Day 1 of trial treatment; non-cytotoxic chemotherapy or investigational agent with limited potential for delayed toxicity is permitted if terminated at least 5 half-lives prior to Day 1 of trial treatment.
  • Extensive prior radiotherapy on more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation.
  • The subject has not recovered from toxicity due to prior therapy to baseline or v4.0 of Grade 1 or less (except alopecia).
  • The subject has poor organ or marrow function as defined in protocol.
  • History of central nervous system (CNS) or primary CNS tumor, unless subject has been previously treated for these conditions, is asymptomatic and has had no requirement for anticonvulsants or high dose for a minimum of 2 weeks prior to entry into the trial.
  • History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of Day 1 of trial drug treatment.
  • Recent major surgery or trauma (within the last 28 days), unhealing/open wounds, diabetic ulcers, recent drainage of significant volume of ascites or pleural effusion.
  • History of congestive heart failure, unstable angina, myocardial infarction, symptomatic cardiac conduction abnormality, pacemaker, or other cardiac disease or history of a stroke within 3 months prior to entering the trial.
  • Baseline interval on screening (ECG) (QTc) >= 460 ms or (LVEF) \< 40% on screening echocardiogram.
  • Other uncontrolled intercurrent diseases
  • Retinal degenerative disease (hereditary retinal degeneration or age-related macular degeneration), history of uveitis or history of retinal vein occlusion, or medically relevant abnormal ophthalmology assessments at screening.
  • Known or suspected allergy to pimasertib, temsirolimus, other rapamycins (sirolimus, everolimus, etc.), their , or any agent given in the course of this trial.
  • Immunization with attenuated within one week of trial entry (examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, BCG, etc.).
  • Concomitant use of any medications or substances that are strong inhibitors or inducers of enzyme, including, but not limited to, phenytoin, carbamazepine, barbiturates, azoles, rifampin, phenobarbital, or St. John's Wort.
  • Pregnant or lactating female.
  • Legal incapacity or limited legal capacity.

Additional exclusion criteria also apply.

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Pimasertib 45 mg+Temsirolimus 12.5 mg

    Drug: Pimasertib · Drug: Temsirolimus

  • Experimental
    Pimasertib 45 mg+Temsirolimus 25 mg

    Drug: Pimasertib · Drug: Temsirolimus

  • Experimental
    Pimasertib 75 mg+Temsirolimus 25 mg

    Drug: Pimasertib · Drug: Temsirolimus

Interventions

  • Pimasertib will be administered in fasted state at a dose of 45 mg once daily orally on Days 1 to 15. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.

    Also known as: MSC1936369B

  • Pimasertib will be administered in fasted state at a dose of 75 mg once daily orally on Days 1 to 15. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.

    Also known as: MSC1936369B

  • Temsirolimus will be administered at a dose of 12.5 mg as intravenous infusion over a 30-60 minute period once a week within 10 minutes after administration of pimasertib on Days 1, 8 and 15 in successive 21-day cycles. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.

  • Temsirolimus will be administered at a dose of 25 mg as intravenous infusion over a 30-60 minute period once a week within 10 minutes after administration of pimasertib on Days 1, 8 and 15 in successive 21-day cycles. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Dose Limiting Toxicities (DLTs)

    DLT was defined as any of the following toxicities graded as per National Cancer Institute (NCI) common terminology criteria for adverse events (NCI CTCAE v4.0) encountered within cycle 1 of treatment at any dose level and judged not to be related to the underlying disease or concomitant medications. A treatment emergent adverse event (TEAE) of potential clinical significance such that further dose escalation would expose subjects to unacceptable risk; any Grade \>=3 non-hematological toxicity except Grade 3 asymptomatic increases in liver function tests, diarrhea, nausea or vomiting with duration \<= 48 hours and alopecia; Grade 4 neutropenia of \>5 days duration or febrile neutropenia of \>1 day duration; Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia; any treatment interruption \>2 weeks due to adverse events; any severe, impairing daily functions or life-threatening, complication or abnormality not defined in NCI-CTCAE that is attributable to the therapy.

    Time frame: Up to 21 Days (within Cycle 1)

Secondary outcomes

  1. Number of Subjects With Treatment-emergent Adverse Events (TEAEs)

    An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. The TEAEs were those events that occur between first dose of trial treatment and up to 30 days after last dose of the trial treatment that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: From the start of the trial treatment until data cut-off date (23 February 2012)

  2. Maximum Plasma Concentration (Cmax) of Pimasertib

    Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

    Time frame: Drug-drug interaction (DDI) cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

  3. Maximum Plasma Concentration (Cmax) of Temsirolimus

    Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

    Time frame: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 8

  4. Time to Reach Maximum Plasma Concentration (Tmax) of Pimasertib

    Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

    Time frame: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

  5. Time to Reach Maximum Plasma Concentration (Tmax) of Temsirolimus

    Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

    Time frame: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

  6. Area Under the Concentration Time Curve During a Dosing Interval (AUCtau) and Area Under the Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of Pimasertib

    The AUCtau was defined as the area under the concentration curve divided by the dosing interval. AUC(0-inf) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

    Time frame: DDI cohorts: Days 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1 for AUCtau; DDI cohorts: Day 1 of Cycle 1 AUC0-inf

  7. Area Under Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of Temsirolimus

    The AUC(0-inf) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

    Time frame: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

  8. Apparent Terminal Half-life (t1/2) of Pimasertib

    The t1/2 was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

    Time frame: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

  9. Apparent Terminal Half-life (t1/2) of Temsirolimus

    The t1/2 was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

    Time frame: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

  10. Apparent Clearance From Plasma Following Oral Administration (CL/f) of Pimasertib

    Clearance (CL) of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. The CL obtained after oral dose (CL/F) was influenced by the fraction of the dose absorbed (bioavailability). Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

    Time frame: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

  11. Total Body Clearance From Plasma Following Intravenous Administration (CL) of Temsirolimus

    The clearance of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

    Time frame: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

  12. Apparent Volume of Distribution (Vz/F) of Pimasertib

    Volume of distribution (Vz) was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. The Vz after oral dose (Vz/F) was influenced by the fraction absorbed. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

    Time frame: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

  13. Volume of Distribution (Vz) of Temsirolimus

    The Vz was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

    Time frame: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

  14. Number of Subjects With Disease Control Rate

    Disease control is defined as confirmed complete response (CR), partial response (PR), or stable disease (SD) \>=12 weeks), based on tumor assessments as determined by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.0. CR: The disappearance of all lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the sum of the longest diameter at baseline. SD: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum of the longest diameter since treatment started.

    Time frame: From the start of the trial treatment until data cut-off date (23 February 2012)

  15. Phospho Extracellular Signal Regulated Kinase (pERK ) Levels and Phospho Ribosomal Protein S6 (pS6) Levels in in Peripheral Blood Mononuclear Cells (PBMCs)

    During the first cycle (either Cycle 1 non-DDI or Cycle 1-DDI) blood samples will be collected for pharmacodynamic marker assessments by flow cytometry such as phospho-ERK and phospho- S6 activities in PBMCs

    Time frame: DDI cohorts: Days 1, 9 and 10 of Cycle 1; Non-DDI cohorts: Days 1, 8 and 9 of Cycle 1

07

Results

Posted Jul 30, 2018
Limitations and caveats
No formal efficacy evaluation was performed for this trial due to early termination of the trial.

Participant flow

First/last subject (informed consent): 27 May 2011/23 August 2012. Last subject completed: 23 February 2012; Subjects randomized at 2 centers in United States.

Participant flow — Overall Study
MilestonePimasertib 45 mg+Temsirolimus 12.5 mgPimasertib 45 mg+Temsirolimus 25 mgPimasertib 75 mg+Temsirolimus 25 mg
Started4236
Completed4236
Not completed000

Outcome measures

PrimaryNumber of Subjects With Dose Limiting Toxicities (DLTs)

DLT was defined as any of the following toxicities graded as per National Cancer Institute (NCI) common terminology criteria for adverse events (NCI CTCAE v4.0) encountered within cycle 1 of treatment at any dose level and judged not to be related to the underlying disease or concomitant medications. A treatment emergent adverse event (TEAE) of potential clinical significance such that further dose escalation would expose subjects to unacceptable risk; any Grade \>=3 non-hematological toxicity except Grade 3 asymptomatic increases in liver function tests, diarrhea, nausea or vomiting with duration \<= 48 hours and alopecia; Grade 4 neutropenia of \>5 days duration or febrile neutropenia of \>1 day duration; Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia; any treatment interruption \>2 weeks due to adverse events; any severe, impairing daily functions or life-threatening, complication or abnormality not defined in NCI-CTCAE that is attributable to the therapy.

Time frame:
Up to 21 Days (within Cycle 1)
Reported as:
Number · subjects
Number of Subjects With Dose Limiting Toxicities (DLTs)
subjectsPimasertib 45 mg+Temsirolimus 12.5 mgPimasertib 45 mg+Temsirolimus 25 mgPimasertib 75 mg+Temsirolimus 25 mg
Number of Subjects With Dose Limiting Toxicities (DLTs)072
SecondaryNumber of Subjects With Treatment-emergent Adverse Events (TEAEs)

An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. The TEAEs were those events that occur between first dose of trial treatment and up to 30 days after last dose of the trial treatment that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
From the start of the trial treatment until data cut-off date (23 February 2012)
Reported as:
Number · subjects
Number of Subjects With Treatment-emergent Adverse Events (TEAEs)
subjectsPimasertib 45 mg+Temsirolimus 12.5 mgPimasertib 45 mg+Temsirolimus 25 mgPimasertib 75 mg+Temsirolimus 25 mg
Number of Subjects With Treatment-emergent Adverse Events (TEAEs)4236
SecondaryMaximum Plasma Concentration (Cmax) of Pimasertib

Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

Time frame:
Drug-drug interaction (DDI) cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
Reported as:
Median · nanogram/milliliter
Maximum Plasma Concentration (Cmax) of Pimasertib
nanogram/milliliterPimasertib 45 mg+Temsirolimus 12.5 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI)
DDI: Day 1185.2 (87.38 to 266.5)193.5 (97.24 to 326.5)——
DDI: Day 9131 (68.75 to 190.5)192.1 (63.8 to 406)——
Non-DDI: Day 8——197.6 (73.75 to 317.3)308.1 (157.3 to 460)
SecondaryMaximum Plasma Concentration (Cmax) of Temsirolimus

Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

Time frame:
DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 8
Reported as:
Median · nanogram/milliliter
Maximum Plasma Concentration (Cmax) of Temsirolimus
nanogram/milliliterPimasertib 45 mg+Temsirolimus 12.5 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI)
DDI: Day 9457.5 (361.6 to 578.1)505.3 (396.8 to 591.4)——
DDI: Day 16281.1 (13.21 to 636.4)511.8 (184.6 to 575.9)——
Non-DDI: Day 8——489.9 (391.9 to 525.5)480.9 (323.3 to 589.7)
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of Pimasertib

Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

Time frame:
DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
Reported as:
Median · hour
Time to Reach Maximum Plasma Concentration (Tmax) of Pimasertib
hourPimasertib 45 mg+Temsirolimus 12.5 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI)
DDI: Day 11 (0.5333 to 2)1.5 (0 to 4)——
DDI: Day 92.3 (0.9167 to 4.033)1.133 (0.5 to 2.667)——
Non-DDI: Day 8——1.5 (1 to 3.967)0.5833 (0.5 to 3)
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of Temsirolimus

Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

Time frame:
DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
Reported as:
Median · hour
Time to Reach Maximum Plasma Concentration (Tmax) of Temsirolimus
hourPimasertib 45 mg+Temsirolimus 12.5 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI)
DDI: Day 90.7417 (0.5167 to 1)0.5667 (0.5 to 1.017)——
DDI: Day 160.9333 (0.5 to 24.05)0.5 (0.5 to 1.55)——
Non-DDI: Day 8——0.5 (0.5 to 0.55)0.55 (0.4333 to 0.5833)
SecondaryArea Under the Concentration Time Curve During a Dosing Interval (AUCtau) and Area Under the Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of Pimasertib

The AUCtau was defined as the area under the concentration curve divided by the dosing interval. AUC(0-inf) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

Time frame:
DDI cohorts: Days 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1 for AUCtau; DDI cohorts: Day 1 of Cycle 1 AUC0-inf
Reported as:
Median · hour*nanogram/milliliter
Area Under the Concentration Time Curve During a Dosing Interval (AUCtau) and Area Under the Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of Pimasertib
hour*nanogram/milliliterPimasertib 45 mg+Temsirolimus 12.5 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI)
DDI: AUCtau: Day 9628 (435.6 to 1338)805 (264.3 to 1623)——
Non-DDI: AUCtau: Day 8——706 (333.8 to 2548)1402 (922.2 to 1735)
DDI: AUC0-inf: Day 1573.2 (393.5 to 1703)828.6 (373.3 to 1310)——
SecondaryArea Under Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of Temsirolimus

The AUC(0-inf) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

Time frame:
DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
Reported as:
Median · hour*nanogram/milliliter
Area Under Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of Temsirolimus
hour*nanogram/milliliterPimasertib 45 mg+Temsirolimus 12.5 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI)
DDI: Day 92452 (1670 to 4440)2130 (1534 to 3642)——
DDI: Day 162006 (1174 to 2837)2743 (1977 to 3219)——
Non-DDI: Day 8——4026 (2386 to 4783)2194 (1324 to 2483)
SecondaryApparent Terminal Half-life (t1/2) of Pimasertib

The t1/2 was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

Time frame:
DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
Reported as:
Median · hour
Apparent Terminal Half-life (t1/2) of Pimasertib
hourPimasertib 45 mg+Temsirolimus 12.5 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI)
DDI: Day 15.915 (4.718 to 6.652)5.886 (2.504 to 20.25)——
DDI: Day 96.08 (2.101 to 11.17)5.896 (2.013 to 23.86)——
Non-DDI: Day 8——7.746 (5.625 to 9.993)5.712 (2.365 to 8.656)
SecondaryApparent Terminal Half-life (t1/2) of Temsirolimus

The t1/2 was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

Time frame:
DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
Reported as:
Median · hour
Apparent Terminal Half-life (t1/2) of Temsirolimus
hourPimasertib 45 mg+Temsirolimus 12.5 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI)
DDI: Day 925.57 (10.39 to 54.46)13.2 (9.237 to 34.92)——
DDI: Day 1620.62 (12.97 to 28.27)19.14 (13.54 to 25.82)——
Non-DDI: Day 8——29.08 (26.14 to 44.14)10.42 (9.192 to 13.76)
SecondaryApparent Clearance From Plasma Following Oral Administration (CL/f) of Pimasertib

Clearance (CL) of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. The CL obtained after oral dose (CL/F) was influenced by the fraction of the dose absorbed (bioavailability). Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

Time frame:
DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
Reported as:
Median · liter/hour
Apparent Clearance From Plasma Following Oral Administration (CL/f) of Pimasertib
liter/hourPimasertib 45 mg+Temsirolimus 12.5 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI)
DDI: Day 181.25 (26.42 to 114.4)54.36 (34.36 to 120.6)——
DDI: Day 971.99 (33.63 to 103.3)55.9 (27.73 to 170.3)——
Non-DDI: Day 8——64.31 (17.66 to 134.8)53.6 (43.22 to 81.33)
SecondaryTotal Body Clearance From Plasma Following Intravenous Administration (CL) of Temsirolimus

The clearance of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

Time frame:
DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
Reported as:
Median · liter/hour
Total Body Clearance From Plasma Following Intravenous Administration (CL) of Temsirolimus
liter/hourPimasertib 45 mg+Temsirolimus 12.5 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI)
DDI: Day 95.378 (2.815 to 7.486)11.73 (6.863 to 16.29)——
DDI: Day 167.528 (4.406 to 10.65)9.292 (7.766 to 12.64)——
Non-DDI: Day 8——6.284 (5.227 to 10.48)11.39 (10.07 to 18.89)
SecondaryApparent Volume of Distribution (Vz/F) of Pimasertib

Volume of distribution (Vz) was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. The Vz after oral dose (Vz/F) was influenced by the fraction absorbed. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

Time frame:
DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
Reported as:
Median · liter
Apparent Volume of Distribution (Vz/F) of Pimasertib
literPimasertib 45 mg+Temsirolimus 12.5 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)Pimasertib 75 mg+Temsirolimus (TEM) 25 mg (Non-DDI)
DDI: Day 1691.3 (210.3 to 923)536.5 (199.4 to 1450)——
DDI: Day 9517.6 (274.4 to 1080)519.5 (157.3 to 1768)——
Non-DDI: Day 8——760.6 (143.3 to 1840)416.5 (190.4 to 745.5)
SecondaryVolume of Distribution (Vz) of Temsirolimus

The Vz was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan.

Time frame:
DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
Reported as:
Median · liter
Volume of Distribution (Vz) of Temsirolimus
literPimasertib 45 mg+Temsirolimus 12.5 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (DDI)Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI)
DDI: Day 9152 (99.01 to 326.1)244.5 (142.2 to 505.4)——
DDI: Day 16189.5 (179.6 to 199.3)233 (216.1 to 394.4)——
Non-DDI: Day 8——309.7 (203.6 to 471.3)172.9 (133.5 to 375)
SecondaryNumber of Subjects With Disease Control Rate

Disease control is defined as confirmed complete response (CR), partial response (PR), or stable disease (SD) \>=12 weeks), based on tumor assessments as determined by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.0. CR: The disappearance of all lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the sum of the longest diameter at baseline. SD: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum of the longest diameter since treatment started.

Time frame:
From the start of the trial treatment until data cut-off date (23 February 2012)

No measurements were reported for this outcome.

SecondaryPhospho Extracellular Signal Regulated Kinase (pERK ) Levels and Phospho Ribosomal Protein S6 (pS6) Levels in in Peripheral Blood Mononuclear Cells (PBMCs)

During the first cycle (either Cycle 1 non-DDI or Cycle 1-DDI) blood samples will be collected for pharmacodynamic marker assessments by flow cytometry such as phospho-ERK and phospho- S6 activities in PBMCs

Time frame:
DDI cohorts: Days 1, 9 and 10 of Cycle 1; Non-DDI cohorts: Days 1, 8 and 9 of Cycle 1

No measurements were reported for this outcome.

Adverse events

Collected over From the start of the trial treatment until data cut-off date (23 February 2012). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pimasertib 45 mg+Temsirolimus 12.5 mg—3/4 (75%)4/4 (100%)
Pimasertib 45 mg+Temsirolimus 25 mg—17/23 (73.9%)23/23 (100%)
Pimasertib 75 mg+Temsirolimus 25 mg—5/6 (83.3%)6/6 (100%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventPimasertib 45 mg+Temsirolimus 12.5 mgPimasertib 45 mg+Temsirolimus 25 mgPimasertib 75 mg+Temsirolimus 25 mg
StomatitisGastrointestinal disorders0/42/232/6
Back painMusculoskeletal and connective tissue disorders0/41/232/6
NauseaGastrointestinal disorders1/40/231/6
VomitingGastrointestinal disorders1/40/231/6
Abdominal pain lowerGastrointestinal disorders1/40/230/6
DiarrhoeaGastrointestinal disorders1/40/230/6
Enterocutaneous fistulaGastrointestinal disorders1/40/230/6
Abdominal wall abscessInfections and infestations1/40/230/6
FallInjury, poisoning and procedural complications1/40/230/6
Balance disorderNervous system disorders1/40/230/6
Most frequent other events
Showing 10 of 178
Most frequent other events
EventPimasertib 45 mg+Temsirolimus 12.5 mgPimasertib 45 mg+Temsirolimus 25 mgPimasertib 75 mg+Temsirolimus 25 mg
ThrombocytopeniaBlood and lymphatic system disorders1/413/235/6
StomatitisGastrointestinal disorders2/415/235/6
RashSkin and subcutaneous tissue disorders0/46/235/6
AnaemiaBlood and lymphatic system disorders3/49/232/6
Rash macularSkin and subcutaneous tissue disorders3/41/230/6
FatigueGeneral disorders2/413/232/6
PyrexiaGeneral disorders2/45/231/6
DiarrhoeaGastrointestinal disorders1/49/231/6
Decreased appetiteMetabolism and nutrition disorders0/49/231/6
HypokalaemiaMetabolism and nutrition disorders1/48/230/6

Baseline characteristics

The safety analysis set included all the subjects who received at least one administration of trial medication.

Age, Continuous
Age, Continuous(years)Pimasertib 45 mg+Temsirolimus 12.5 mgPimasertib 45 mg+Temsirolimus 25 mgPimasertib 75 mg+Temsirolimus 25 mgTotal
Mean63.3 ± 11.3057.9 ± 14.0955.5 ± 6.1958.1 ± 12.61
Sex: Female, Male
Sex: Female, Male(Participants)Pimasertib 45 mg+Temsirolimus 12.5 mgPimasertib 45 mg+Temsirolimus 25 mgPimasertib 75 mg+Temsirolimus 25 mgTotal
Female216422
Male27211
08

Study locations

3 sites
  • Cedars-Sinai Medical Center
    Los Angeles, California, United States
  • For Recruiting Locations in the US contact US Medical Information in
    Rockland, Massachusetts, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas, United States
09

References and documents

Publications

  • Mita M, Fu S, Piha-Paul SA, Janku F, Mita A, Natale R, Guo W, Zhao C, Kurzrock R, Naing A. Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors. Invest New Drugs. 2017 Oct;35(5):616-626. doi: 10.1007/s10637-017-0442-3. Epub 2017 Feb 13. PubMed 28194539 ↗
  • Liu X, Lorusso P, Mita M, Piha-Paul S, Hong DS, Fu S, McQuinn L, Asatiani E, Doyle LA, Chen HX, Hess KR, Kurzrock R, Naing A. Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist. 2014 Apr;19(4):426-8. doi: 10.1634/theoncologist.2013-0231. Epub 2014 Mar 25. PubMed 24668327 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2011 to primary completion in Feb 2012, 8 months.

Results were first posted in Jul 2018, 6 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2011
First posted
Jun 22, 2011
StartActual
May 27, 2011
Primary completionActual
Feb 23, 2012
CompletionActual
Feb 23, 2012
Results first posted
Jul 30, 2018
Last update
Jul 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01378377
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
Jun 22, 2011
Start date
May 27, 2011
Primary completion
Feb 23, 2012
Completion
Feb 23, 2012
Results posted
Jul 30, 2018
Last update
Jul 30, 2018

Study contacts

Medical Responsible
study director · EMD Serono, an affiliate of MerckKGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pimasertib

Start the discussion